Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,416 | 276 | 1,111 |
| Samples | 1,198 | 231 | 952 |
| Peptides | 911 | 149 | 771 |
Function
DOCK3 · Dedicator of cytokinesis 3
This gene is specifically expressed in the central nervous system (CNS). It encodes a member of the DOCK (dedicator of cytokinesis) family of guanine nucleotide exchange factors (GEFs). This protein, dedicator of cytokinesis 3 (DOCK3), is also known as modifier of cell adhesion (MOCA) and presenilin-binding protein (PBP). The DOCK3 and DOCK1, -2 and -4 share several conserved amino acids in their DHR-2 (DOCK homology region 2) domains that are required for GEF activity, and bind directly to WAVE proteins [Wiskott-Aldrich syndrome protein (WASP) family Verprolin-homologous proteins] via their DHR-1 domains. The DOCK3 induces axonal outgrowth in CNS by stimulating membrane recruitment of the WAVE complex and activating the small G protein Rac1. This gene is associated with an attention deficit hyperactivity disorder-like phenotype by a complex chromosomal rearrangement. [provided by RefSeq, Aug 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000266037 | Q8IZD9 | 1,416 | 911 |
Gene Properties
Recurrent Mutations
All 912 amino-acid changes on canonical ENST00000266037 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in DOCK3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in DOCK3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Melanoma | 32/210 15% | 255/1899 13% |
| Endometrial Carcinoma | 11/42 26% | 45/612 7% |
| Acute Myeloid Leukemia | 7/90 8% | 0/0 0% |
| Hodgkins Lymphoma | 6/16 38% | 4/122 3% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Colorectal Carcinoma | 22/143 15% | 133/3239 4% |
| Chondrosarcoma | 3/14 21% | 1/75 1% |
| Gastric Carcinoma | 7/74 9% | 65/1809 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Other Solid Cancers | 6/94 6% | 51/1515 3% |
| Cervical Carcinoma | 3/35 9% | 12/422 3% |
| Squamous Cell Lung Carcinoma | 9/57 16% | 17/810 2% |
| Non-Small Cell Lung Carcinoma | 16/304 5% | 34/1390 2% |
| Other Sarcomas | 3/69 4% | 16/699 2% |
| Neuroendocrine Tumour | 14/154 9% | 3/577 1% |
| Ovarian Carcinoma | 5/109 5% | 20/998 2% |
| Germ Cell Tumour | 0/25 0% | 4/169 2% |
| Small Cell Lung Carcinoma | 1/9 11% | 14/752 2% |
| Hepatocellular Carcinoma | 3/46 7% | 41/2210 2% |
| Bladder Carcinoma | 2/58 3% | 16/956 2% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Head and Neck Carcinoma | 5/85 6% | 21/1574 1% |
| Plasma Cell Myeloma | 3/44 7% | 2/305 1% |
| Neuroblastoma | 8/87 9% | 11/1331 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 21/1592 1% |
| Esophageal Carcinoma | 0/23 0% | 10/769 1% |
| Ewings Sarcoma | 2/63 3% | 2/262 1% |
| Non-Cancerous | 4/104 4% | 7/830 1% |
Mutation Distribution
Where DOCK3 is mutated · all tissues, split by cell line vs tissue
How many mutations in DOCK3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,416 mutations in DOCK3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|